Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
188-0551
- Development stage
- Phase 3
- Lead developer
- Avecho Biotechnology
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
188-0551 is a topical small molecule drug developed for the treatment of stable, moderate to severe plaque psoriasis. It has been evaluated in multiple Phase 3 clinical trials as a spray or solution formulation applied twice daily to affected skin areas. The drug's mechanism of action has not been publicly disclosed and is listed as "No Mechanism" in available sources. Clinical studies have focused on its efficacy, safety, and potential for adrenal suppression compared to reference corticosteroid drugs. The product was initially developed by Avecho Biotechnology and later advanced by Therapeutics.
- Other names
- 188-0551 solution188-0551 spray
Beyond the preview
Go deeper on 188-0551.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 188-0551.